The Korean pharmaceutical and biotechnology industry aim to introduce solid cancer-targeting CAR-T with new mechanisms of action (MOA).

Chimeric antigen receptor T (CAR-T) cell therapy is an immune cell therapy for cancer treatment designed to deliver genetic material to T cells to produce the CAR in patients. CAR-T has not been approved for indications in solid cancer because the tumor microenvironment, such as fibroblasts in tumor tissues, limits T-cell modifying CAR-T from T-cell infiltration, posing barriers to discovering target antigens. All of the commercialized treatments, including Novartis’ Kymriah, Gilead Science’s Yescarta, and BMS’ Breyanzi, have been approved for blood cancers.
<